Literature DB >> 17825390

Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology.

Andrew J Li1, R Geoffrey Elmore, James C Pavelka, Beth Y Karlan.   

Abstract

OBJECTIVE: Epidemiologic data suggest that aberrant androgen homeostasis may promote aggressive epithelial ovarian cancer biology. Hyperandrogenism results from both obesity and expression of polymorphic androgen receptor (AR) allelotypes harboring short cytosine-adenine-guanine (CAG) repeat sequences; both have been shown to independently correlate with poor overall survival in ovarian cancer. We have hypothesized that the combination of these factors further manifests an aggressive ovarian cancer phenotype.
METHODS: Genotype analysis of the AR CAG polymorphism was performed on 81 patients with papillary serous epithelial ovarian cancer. Medical records were reviewed for body mass index (BMI), clinico-pathologic factors, and survival. Data were examined using the Fishers exact test, Kaplan-Meier survival, and Cox regression analyses.
RESULTS: Overweight or obese women (BMI > or = 25) with a short AR allele (< or = 19 CAG repeats) demonstrated statistically shorter progression-free survival (9 months) when compared to underweight or ideal body weight women (BMI < 25) and a long AR allele (> 19 CAG repeats; 26 months, p=0.0002). Overweight/obese women with a short AR allele also demonstrated shorter overall survival (34 months) when compared to underweight/ideal body weight women with a long AR allele (59 months, p=0.036). On multivariate analyses, the combination of a short AR allele and BMI > 25 was an independent poor prognostic factor after controlling for age, stage, grade, optimal cytoreduction, and AR allele length and BMI independently (p=0.05).
CONCLUSION: These data provide further evidence that suggest that hyperandrogenism promotes an aggressive epithelial ovarian cancer phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825390     DOI: 10.1016/j.ygyno.2007.07.059

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

Review 1.  Revisiting the role of antiandrogen strategies in ovarian cancer.

Authors:  Dionysis Papadatos-Pastos; Konstantin J Dedes; Johann S de Bono; Stanley B Kaye
Journal:  Oncologist       Date:  2011-09-23

2.  Individual- and neighborhood-level education influences the effect of obesity on prostate cancer treatment failure after prostatectomy.

Authors:  Charnita Zeigler-Johnson; Knashawn H Morales; Karen Glanz; Elaine Spangler; Jonathan Mitchell; Timothy R Rebbeck
Journal:  Cancer Causes Control       Date:  2015-07-14       Impact factor: 2.506

3.  Sex hormone-binding globulin (SHBG) expression in ovarian carcinomas and its clinicopathological associations.

Authors:  Ruixia Huang; Yuanyuan Ma; Ruth Holm; Claes G Trope; Jahn M Nesland; Zhenhe Suo
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

4.  The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer.

Authors:  Kosj Yamoah; Charnita M Zeigler-Johnson; Abra Jeffers; Bruce Malkowicz; Elaine Spangler; Jong Y Park; Alice Whittemore; Timothy R Rebbeck
Journal:  BMC Cancer       Date:  2016-07-29       Impact factor: 4.430

Review 5.  The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications.

Authors:  Haiyan Zhu; Xuejie Zhu; Lihong Zheng; Xiaoli Hu; LuZhe Sun; Xueqiong Zhu
Journal:  Oncotarget       Date:  2017-04-25

6.  Assessment of expression levels of leptin and leptin receptor as potential biomarkers for risk of prostate cancer development and aggressiveness.

Authors:  Hala Fawzy Mohamed Kamel; Anmar M Nassir; Abeer A Al Refai
Journal:  Cancer Med       Date:  2020-06-23       Impact factor: 4.452

Review 7.  The Role of Androgen Receptor Signaling in Ovarian Cancer.

Authors:  Taichi Mizushima; Hiroshi Miyamoto
Journal:  Cells       Date:  2019-02-19       Impact factor: 6.600

Review 8.  Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment.

Authors:  Adele Chimento; Ivan Casaburi; Paola Avena; Francesca Trotta; Arianna De Luca; Vittoria Rago; Vincenzo Pezzi; Rosa Sirianni
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-21       Impact factor: 5.555

9.  The androgen receptor cytosine-adenine-guanine repeat length contributes to the development of epithelial ovarian cancer.

Authors:  Xiangrui Meng; Peng Lu; Zhi Chu; Qingxia Fan
Journal:  Oncotarget       Date:  2016-01-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.